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Abstract
Background: Despite the increasing popularity of multi-model comparison studies and their ability to inform
policy recommendations, clear guidance on how to conduct multi-model comparisons is not available. Herein,
we present guidelines to provide a structured approach to comparisons of multiple models of interventions
against infectious diseases. The primary target audience for these guidelines are researchers carrying out model comparison
studies and policy-makers using model comparison studies to inform policy decisions.
Methods: The consensus process used for the development of the guidelines included a systematic review of
existing model comparison studies on effectiveness and cost-effectiveness of vaccination, a 2-day meeting and
guideline development workshop during which mathematical modellers from different disease areas critically discussed
and debated the guideline content and wording, and several rounds of comments on sequential versions of the
guidelines by all authors.
Results: The guidelines provide principles for multi-model comparisons, with specific practice statements on what
modellers should do for six domains. The guidelines provide explanation and elaboration of the principles and practice
statements as well as some examples to illustrate these. The principles are (1) the policy and research question – the
model comparison should address a relevant, clearly defined policy question; (2) model identification and selection –
the identification and selection of models for inclusion in the model comparison should be transparent and minimise
selection bias; (3) harmonisation – standardisation of input data and outputs should be determined by the research
question and value of the effort needed for this step; (4) exploring variability – between- and within-model variability
and uncertainty should be explored; (5) presenting and pooling results – results should be presented in an appropriate
way to support decision-making; and (6) interpretation – results should be interpreted to inform the policy question.
Conclusion: These guidelines should help researchers plan, conduct and report model comparisons of infectious
diseases and related interventions in a systematic and structured manner for the purpose of supporting health policy
decisions. Adherence to these guidelines will contribute to greater consistency and objectivity in the approach and
methods used in multi-model comparisons, and as such improve the quality of modelled evidence for policy.
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Background
Infectious disease modelling
Health interventions such as vaccines, diagnostics and
treatments have greatly reduced suffering and the number
of premature deaths due to infectious diseases over the
last century. In addition to reducing morbidity and mor-
tality, when highly effective and implemented at a global
scale, health interventions can contribute to disease elim-
ination and eradication. However, infectious diseases still
account for a substantial disease burden, especially in low-
and middle-income countries and, therefore, further opti-
misation of strategies for their prevention and control are
needed.
Mathematical models play a pivotal role in supporting
policy decisions about the deployment of health interven-
tions by synthesising evidence about infectious disease
epidemiology to provide estimates of the long-term, popula-
tion-level health impact of interventions [1]. As such, they
can inform key questions regarding disease eradication,
elimination and control [2]. Health economic modelling can
also provide an estimate of economic impact, including
risk–benefit, cost-effectiveness, equity and affordability [3].
However, the modelling of infectious diseases has unique
complexities related to infectious disease transmission, herd
immunity and sources of heterogeneity in rates of infection
and disease. These distinct characteristics of infectious
diseases mean that disease interventions often have popula-
tion-level effects that are complex and non-linear. Optimis-
ing decisions with regard to interventions, such as the
groups to target or the level of coverage to aim for, often re-
quires more analytically complex models, such as transmis-
sion dynamic models, that require more behavioural and
epidemiological information to parameterise [3].
Uncertainties in infectious disease modelling arise from
epidemiological, model parameter and structural uncer-
tainties resulting from the fact that some processes need
to be simplified or are not fully understood such as, for
example, the natural history of disease (e.g. in the case of
many of the neglected tropical diseases and tuberculosis)
[2, 4] or people’s behaviour (e.g. sexual activity for sexually
transmitted diseases or screening behaviour). Simplifica-
tions and shortage of information or data require model-
lers to make assumptions. Since the various modelling
groups can choose different modelling approaches, make
distinct assumptions, and use different data to address a
decision problem or policy question [5], models can pro-
duce disparate results, sometimes leading to different
policy recommendations.
Rationale for multi-model comparisons
According to a recent systematic review of the literature on
model comparisons of effectiveness and cost-effectiveness of
vaccination, multi-model comparison studies have been per-
formed in the past to synthesise, compare and understand
different models’ predictions of the effectiveness and/or
cost-effectiveness of an intervention in order to assess
model-based evidence for policy-making [6]. More specific-
ally, the systematic review highlighted that model compari-
son studies have been performed to (1) describe the models
that have been used to examine a policy question, (2) better
understand the impact of model inputs, model structure, as-
sumptions and parameters on predictions, (3) characterise
the robustness of different model predictions to changes in
these inputs, structures, assumptions and parameters to
assess their impact for policy recommendations, and/or (4)
synthesise conclusions from several models in order to in-
form policy recommendations [6]. Furthermore, the process
of going through a model comparison yields other benefits,
including improved collaboration between different model-
ling groups and accelerated spread of technical knowledge
to both the modelling community and to non-modellers. It
may also enhance the identification of data gaps, guidance
of future research, and communication between modellers
and decision-makers. Multi-model comparisons may thus
have the potential to provide the highest standard of evi-
dence as well as a more rigorous, relevant and unbiased syn-
thesis of current knowledge obtained by mathematical
modelling. However, there are also disadvantages of multi-
model comparisons; they involve additional time and re-
sources that could be used to model new scenarios and
there is also the possibility that independent groups will
converge their model parameters and assumptions following
comparison and discussion with other groups, such that the
models are no longer totally independent.
Rationale for the multi-model comparison guidelines
Multi-model comparison studies are becoming increas-
ingly popular. For the field of vaccination alone, 115
multi-model comparison studies were identified in a
recent systematic review, more than half of which were
published since 2011 [6]. Multi-model comparisons have
also been performed for non-communicable diseases such
as diabetes, cancer and chronic obstructive pulmonary dis-
ease [7–9] as well as for questions unrelated to vaccines
for infectious diseases [10–15]. However, contrary to other
methods of data synthesis, such as systematic reviews and
meta-analysis of empirical studies, no clear guidelines exist
on how to conduct multi-model comparisons [6]. The
guidelines presented herein thus fill a gap and aim to pro-
vide a systematic and structured approach to model com-
parison by presenting principles and practices of model
comparisons for interventions against infectious diseases.
The guidelines also aim to help researchers improve the
completeness and transparency of reporting multi-model
comparisons; this should enhance the quality and trans-
parency of multi-model comparison studies and ultimately
provide better tools for decision-making.
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Methods
Process and stakeholders
These guidelines were requested by the Immunization
and Vaccines-related Implementation Research Advisory
Committee (IVIR-AC) from the World Health
Organization (WHO) [16]. IVIR-AC advises WHO on
the relevance and applicability of implementation re-
search, including mathematical models and multi-model
comparisons for global vaccine recommendations. IVIR-
AC recommends multi-model comparisons, rather than
single models, to strengthen the evidence underlying
policy decisions [17] and has coordinated or commis-
sioned several model comparisons in the past [18–22],
some of which have led to changes in WHO recommen-
dations [23–25]. However, these model comparisons
were performed on an ad hoc basis, using informal pro-
cedures with various methods.
The guideline development process is described below.
Full details are described in Additional file 1: Section 1.
Briefly, a working group was established, which orga-
nised a 2-day meeting with researchers, policy-makers
and a journal editor interested in multi-model compari-
sons. The purpose of the meeting was twofold; first, it
served to facilitate discussion on best practices between
different disease areas and, second, it was used to obtain
consensus on principles and practices for multi-model
comparisons (see Additional file 1: Section 2 for the
meeting agenda and Additional file 1: Section 3 for the
list of presenters and participants). A systematic review
of the literature on model comparisons of effectiveness
and cost-effectiveness of vaccination provided initial
insight into the key pieces of information that had to be
included [6]. The model comparison guide was written
by the meeting presenters and participants of the work-
shop, coordinated by the working group.
Scope
A multi-model comparison is defined as a formal process
by which outcomes of two or more mathematical models
of health conditions or interventions are used to provide
evidence for a decision. We define mathematical models
for these guidelines as mechanistic disease models. The
outcomes may include immunological (e.g. antibody titres),
clinical (e.g. disease episodes and deaths), epidemiological
(e.g. disease incidence or force of infection) and/or eco-
nomic (e.g. cost-effectiveness ratios) endpoints. Generally,
multi-model comparisons can be for policy (i.e. to answer a
clearly defined policy question by comparing model out-
comes for different scenarios) or can have a purely scientific
purpose of better understanding the underlying drivers of
differences between model predictions. Here, we focus on
multi-model comparisons to support policy decisions re-
lated to infectious diseases. Hence, we exclude comparisons
of models developed purely for better scientific or
epidemiological understanding of a disease without an
obvious policy question as well as model comparisons per-
formed to better estimate disease burden.
Drolet et al.’s [6] review suggested classifying multi-
model comparisons into two categories as (1) comparisons
that were based purely on results available in the public
domain (e.g. journal articles) and (2) comparisons that
were based on generating new model simulations not pre-
viously in the public domain. The focus of the present
guidelines is on the second category. This document does
not provide guidance on how to develop, describe, validate
or fit individual models since guidelines already exist for
good modelling practice in many disease areas [26, 27].
Target audience
The primary target audience for these guidelines are re-
searchers carrying out model comparison studies and
policy-makers using evidence from model comparison
studies to inform policy decisions. The guidelines also
target funding agencies, journal editors and reviewers
who need to understand the methodology and proce-
dures of model comparisons and must be able to assess
the quality of the model comparison.
Results
The principles we describe here should improve the reliabil-
ity, transparency and usefulness of multi-model comparisons
for decision-making. A summary of the principles and prac-
tices, explained in detail below, is provided in Table 1.
In the guidelines, it is assumed that there is a coordin-
ator for the model comparison process. This coordinator
should ideally be a technically skilled, independent per-
son without a model included in the model comparison
exercise; however, for very technical comparisons, some-
one from one of the participating modelling groups may
be needed if there is no independent person with the
skills and knowledge to coordinate the exercise.
If those carrying out model comparisons deviate from
the guidelines, they should be explicit about this and the
reasons for doing so. The guidelines can be adapted for
different situations (e.g. to answer a scientific question).
Because this is a developing field, the guidelines may
need to be updated when new insights or application
areas become available.
Policy and research question
The model comparison should address a relevant, clearly
defined policy question
The focus and the questions that the model comparison is
meant to answer should be determined a priori. Policy-
makers and/or research funders should be involved at an
early stage and throughout the process, and should help
define and refine the questions.
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Although multi-model comparisons are performed to
contribute evidence for policy decisions, they may not ne-
cessarily be the best tool for all policy questions. Whether
the expected outcome of a multi-model comparison is
worth the lengthy resource-intensive process and large
time commitment of the involved modelling groups
should be carefully considered. To avoid non-participation
of modelling groups because of time constraints [22], we
recommend dedicated funding for multi-model compari-
sons, particularly for exercises that assess public health
problems in low- and middle-income countries. The role
of the funding sources should be explicitly mentioned, as
should any potential conflicts of interest.
Good practice
The policy question needs to be refined, operationalised
and converted into a research question through an iterative
process
A precise and answerable research question is essential for
the model comparison process because it shapes the model
comparison approach and analysis. The research question
directly translates into the scenarios tested, decisions
regarding which data to standardise/harmonise and the
assumptions made, e.g. regarding setting. Developing a
question involves operationalising the policy question into
clear scenarios and measurable outputs. Policy-makers’
involvement is essential to ensure that all the important
features of the decision problem are correctly represented
and that relevant intervention scenarios are tested. In
addition, it may be desirable to include disease experts to
provide input on the epidemiological and clinical relevance
of the policy question.
The original policy question that the model compari-
son aims to answer should be agreed upon a priori so
that the model comparison can be completed in a timely
manner to inform policy. If additional policy questions
arise, they should only be added if all parties agree that
answering these questions is feasible and useful. Occa-
sionally, new or refined research questions arise during
the model comparison process; these should be carefully
Table 1 Principles and good practice statements for multi-model comparisons
Principle Good practice
1. Policy and research question: The model comparison
should address a relevant, clearly defined policy question
• The policy question should be refined, operationalised and converted
into a research question through an iterative process
• Process and timelines should be defined in agreement with the policy
question
2. Model identification and selection: The identification and
selection of models for inclusion in the model comparison should
be transparent and minimise selection bias
• All models that can (be adapted to) answer the research question should
be systematically identified, preferably through a combination of a
systematic literature review and open call
• Models should be selected using pre-specified inclusion and exclusion
criteria, and models identified as potentially suitable but not included
should be reported alongside their reason for non-participation
• Models used and changes made as part of the comparison process
should be well documented
• If an internal or external validation was used to limit the model selection,
it should be reported
3. Harmonisation: Standardisation of input and output data
should be determined by the research question and value of the
effort needed for this step
• Developing a pre-specified protocol may be useful; if so, it could be
published with the comparison results
• Modellers should consider fitting models to a common setting or
settings
• Harmonisation of parameters governing the setting, disease, population
and interventions should be considered whilst avoiding changes to
fundamental
model structures leading to model convergence
4. Exploring variability: Between- and within-model variability
and uncertainty should be explored
• Multiple scenarios should be explored to understand the drivers of the
model results
• Sensitivity analysis and what-if analyses (examining extreme scenarios)
should be carried out
5. Presenting and pooling results: Results should be presented
in an appropriate way to support decision-making
• The results for the individual models should be presented, along with
within-model uncertainty ranges
• Summary measures that combine outcomes of models should only be
used if all outcomes support the same policy; it should be clearly
communicated whether summary ranges include within-model
uncertainty or between-model uncertainty (i.e. the range of point
estimates across the model)
6. Interpretation: Results should be interpreted to inform the
policy question
• Key results and their interpretation to policy questions should be discussed
• Key strengths and limitations of the model comparison process and results
should be addressed
• Key recommendations for next steps should be reported
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considered in terms of their added value or – if it is a
long duration comparison – their overriding importance
to provide the most suitable and timely answer to the
initial policy question.
Process and timelines should be defined in agreement with
the policy question
As with any research that aims to be useful for health policy,
multi-model comparisons should be organised to provide
results at the time they are required for decision-making
[28]. Operating within the context of policy decisions fre-
quently requires compromise. The need to produce results
quickly can reduce the opportunities to systematically iden-
tify models, test different scenarios and perform sensitivity
analyses to identify sources of variability between models.
Furthermore, the time and opportunities for stakeholders to
review results, raise questions and refine scenarios may also
be minimised. This is acceptable provided that the meth-
odological limitations imposed by fast-tracking are made
clear and the limitations and weaknesses of the multi-model
comparison are explicitly addressed and/or documented
[28]. In some situations, preliminary results may allow
decisions to be made.
At the start of a multi-model comparison, it should be
clear when the results are needed to support decision-
making. A timeframe should be developed to meet that
target, including sufficient time for review and revision of
scenarios and modelling assumptions. However, develop-
ing a timeframe is potentially challenging; often, questions
are changed or refined during the model comparison
process and the first set of results may lead to decisions to
further harmonise the models. These challenges should be
anticipated and accommodated to the extent possible in
developing timeframes. Furthermore, timelines have to
take into account the constraints imposed by the financial
resources available for the model comparison exercise as
well as by the availability of staff with sufficient expertise
to conduct the exercise.
Model identification and selection
The identification and selection of models for inclusion in
the model comparison should be transparent and
minimise selection bias
Once the research question has been determined, a num-
ber of models need to be selected for inclusion in the
model comparison exercise. The choice of models
depends on the policy question; a definition of the types
of mathematical model that may be included should be
provided, e.g. individual-based models (agent-based
models, microsimulation, etc.), compartmental models,
Markov models, etc. Defining the mathematical models to
be considered for the study will help with the subsequent
development of search terms.
The model selection criteria and process should be
explicitly defined in advance for transparency. The devel-
opment of a study protocol for this phase of the model
comparison, clearly specifying the search terms, search
strategy, and inclusion and exclusion criteria, should be
considered as commonly performed for systematic litera-
ture reviews. In the study protocol, the decision process
for model inclusion should be described, considering, for
example, the level of difference between models in order
for them to be considered independent, the course of
action to be taken when a research group will not or can-
not participate, etc. The person or group conducting the
selection process should also be explicitly stated regardless
of whether they are members of an included modelling
group, an external coordinator commissioned for this
purpose or the funder/decision-maker.
Good practice
All models that can (be adapted to) answer the research
question should be systematically identified, preferably
through a combination of a systematic literature review
and open call
The combination of a systematic literature review and an
open call increases the sensitivity of the search strategy
and the likelihood of identifying all eligible models. A
systematic literature review is a comprehensive search
strategy using explicit search terms and transparent
reporting [29] that generally involves a cascading process
of searching databases of published studies, conference ab-
stracts, and health technology assessment websites and re-
positories, reading and analysing the identified studies,
and iteratively searching the references of studies captured
in the search [30]. Therefore, it has the lowest risk for
selection bias. It may also involve actively contacting
authors to ask if they know of other models. Instead of
conducting a new systematic review, it is also possible to
identify models through an existing systematic review if its
purpose matches that of the comparison.
Whilst model identification based on a systematic re-
view is a good method to avoid selection bias, this requires
time and resources. Furthermore, it may not find models
that are not yet adapted for the research question, unpub-
lished or still in development. There are some potential
disadvantages of including unpublished models, including
lower certainty about quality of models that are not yet
peer reviewed and the likelihood that model specifications
may still change over the course of the comparison. How-
ever, including such models may be particularly important
for new policy questions only recently addressed by mod-
ellers such as evaluating a health technology in early stages
of development. Hence, the systematic review may be sup-
plemented by an open call. An open call means that the
purpose and specifics of the model comparison are widely
advertised and that everyone who thinks they can fulfil the
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pre-specified criteria for the model comparison activity in
a certain timeframe is encouraged to apply to be part of
the model comparison. To achieve its objective, an open
call must reach everyone who has developed a model that
is potentially eligible and therefore should be widely cast,
for example, through advertising on websites or newslet-
ters, announcements at conferences, and active snowbal-
ling through potentially relevant groups. However, this
process is prone to selection bias because it relies on self-
identification of modelling groups and should include an
additional quality check for model inclusion.
Models should be selected using pre-specified inclusion and
exclusion criteria and models identified as potentially
suitable but not included should be reported alongside their
reason for non-participation
Transparency requires a clear description of the identified
models and the decisions made to select these. Selecting
models should, in first instance, be performed using pre-
specified selection criteria (e.g. for model characteristics
and features) determined by the research question (Fig. 1).
Wider inclusion criteria generally introduce greater vari-
ability in model assumptions.
An assessment of methodological quality may be
performed, for example, by requesting that models
are calibrated to epidemiological data and/or that they
observe best practice in modelling and adhere to
model guidelines such as the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
statement [27]. Models may be excluded if, following
data collection, it appears that they cannot be used,
they fail to fit (observed) data, or show results that
are obviously wrong or biologically or mechanistically
impossible and the modellers are not able to correct
these errors (Fig. 1). There should be no minimum
performance criteria for inclusion in a multi-model
comparison, although a subset of models may be se-
lected for a particular analysis provided the reasons
for the selection are reported. Models identified as
potentially suitable but not included should be re-
ported alongside their reason for non-participation,
such as a lack of resources.
Models should be independent, meaning that there
must be a qualitative difference in structure or a funda-
mental difference in the representation or understand-
ing of disease characteristics or transmission networks
across the included models. However, even independ-
ent models may share components and choices of par-
ameterisation of processes and may rely on similar
calibration sources. There is currently no ‘best practice’
approach to characterise model dependence and, often,
this will require the coordinator’s valued judgement.
Fig. 1 Flow diagram for model identification and inclusion
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Models used and changes made as part of the comparison
process should be well documented
Describing the models included in the comparison
allows the audience to generally understand how the
models differ. It serves to highlight model structures,
specific features, data requirements, capabilities and
limitations of the models. Models should ideally be
described in different ways (e.g. words, diagrams,
equations and code) to reduce ambiguity, allow repro-
ducibility, and to facilitate comparisons and informa-
tion exchange across models. The original model, and
any changes made as part of the comparison process,
particularly any changes in the structure of the
models, should be well documented. Parameter values,
their source and their number and type of source
data (e.g. epidemiological study, assumption by au-
thor, model fit from previous work, etc.) can be
described in a table. Details of the models can be
provided in a technical annex. If the technical details
are long and have been previously described, then
they should be either briefly summarised with refer-
ences to other publications or placed in an online
repository.
If an internal or external validation was used to limit the
model selection, it should be reported
Internal validation evaluates the performance of the
model on the population underlying the sample that was
used to develop the model. External validation compares
the results of the model with the best available evidence
[31]. When investigators want to perform an external
validation, it is recommended that this is done with data
that none of the modelling groups has used for the
development and calibration of the model. Often, indi-
vidual models have already undergone some validation.
Additional validation may be performed when new data
become available. However, a strong focus on specific
performance metrics, in particular if they are based on
single datasets, may lead to overconfidence and unjusti-
fied convergence, allow compensating errors in models
to match certain benchmarks, and may prohibit suffi-
cient diversity of models. On the other hand, discussion
and acceptance or rejection of approaches used by indi-
vidual groups, in order to converge to a meaningful set
of common assumptions, is part of the rationale for per-
forming model comparisons, provided that parameters
for which there is actually a paucity of evidence remain
open to interpretation.
Researchers can develop tools to help the validation
process, for example, a standardised format for output-
ting results, including indicators and ‘sanity checks’ to
quickly recognise obvious errors; this also allows for
quicker data handling and processing.
Harmonisation of scenarios, inputs and outputs
Standardisation of input data and outputs should be
determined by the research question and value of the
effort needed for this step
To answer a specific policy question, all models simulate
the same scenario(s) (e.g. target population, intervention
efficacy and coverage) and, possibly, setting (e.g. inci-
dence or prevalence) to determine the extent to which
models agree on the health (and economic) impact of
the intervention(s) [32]. The rationale for standardising
input and output data is that it allows for a more direct
comparison of results and conclusions across models,
which may otherwise not be possible because models
tend to address slightly varying questions, evaluate dif-
ferent scenarios, apply to diverse settings, use differing
assumptions regarding other interventions, and report
different outcome metrics [32]. By standardising certain
assumptions, it is possible to minimise variation in out-
comes resulting from such assumptions. Policy-makers
and modellers might be interested in exploring the effect
of different scenarios, e.g. by varying intervention eligi-
bility, coverage and compliance, or any other assump-
tions over a pre-specified range or set of values.
Output metrics need to be standardised to enable
comparison. The choice of output metrics also depends
on the policy question and can include measures of dis-
ease incidence or prevalence, costs, disability-adjusted
life-years averted and incremental cost-effectiveness
ratios, amongst others. It is recommended to use inter-
mediate outputs (e.g. infection and/or disease) in
addition to final outputs (e.g. deaths).
Good practice
Developing a pre-specified protocol may be useful; if so, it
could be published with the comparison results
Early in the model comparison process, there should be
discussion and mutual understanding about the range of
mechanisms that are being represented in the models.
These should represent what is known (and not known)
about the dynamics of disease transmission from person
to person, the natural history of disease, the efficacy of
available interventions and other fundamentals. Each
modelling group should be free to represent and param-
eterise these processes as they see fit, but an understand-
ing of what is being represented allows for a sharper
analysis of differences in outcomes. In addition, the
terminology used in the comparison should be defined
clearly and in advance (e.g. whether prevalence refers to
point, period or lifetime prevalence).
A pre-specified protocol, developed in collaboration
with all the modelling groups, describes the analyses that
need to be performed and the key outcomes for com-
parison as well as describing which model elements are
standardised; this helps identify the data required by the
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different modelling groups. The protocol might spe-
cify different stages, for example, a first stage in
which no changes are made to the models and a sec-
ond stage with pre-specified changes in the input
data. Having a protocol does not preclude further
iteration and harmonisation. Initial results might lead
to further actions that were not foreseen or specified
in the protocol.
Modellers should consider fitting models to a common
setting or settings
Using data from a common setting to fit models may
be useful depending on the research question. For ex-
ample, for some vector-borne diseases, transmission
setting is very important, whilst, for other diseases,
the specific setting may be less important provided
that the baseline incidence/prevalence is similar. The
model comparison can also be carried out for mul-
tiple settings, reflecting different disease prevalence or
epidemic characteristics [11, 12].
Harmonisation of parameters governing the setting,
disease, population and interventions should be considered
whilst avoiding changes to fundamental model structures
leading to model convergence
Model comparisons are conducted in order to under-
stand the differences between models and to examine
the impact of these model choices. In order to under-
stand key difference drivers, some parameters governing
the setting, disease, population and intervention may
need to be harmonised in order to expose the effect of
structural differences between models. However, if there
are genuine uncertainties around key parameters (such
as disease burden or natural history) then it may be bet-
ter to represent this uncertainty by having the various
models calibrated to different parameter sources.
It is important that parameters are not harmonised
purely to reduce uncertainty in the range of outcomes
predicted by the models, i.e. to make the models con-
verge to a single answer to guide policy [32]. If there are
genuine discrepancies between model predictions due to
lack of certainty, then these should be reported to deci-
sion-makers, who will need to make decisions in the
knowledge that there is uncertainty about the outcomes.
There is no generic approach to harmonisation but,
generally, it requires the isolation of different areas of
uncertainty, e.g. setting, individual parameters and
certain elements of structural uncertainty. However,
modellers should preferably avoid making changes to
fundamental model features such as model structure
and/or ‘deep’ parameters such as probability of transmis-
sion or duration of natural immunity.
Beyond harmonisation of model parameters, modelling
groups may also want to make structural changes to
their models in order to better fit data or because of
knowledge gained from interaction with other modellers
and subject matter experts. Allowing such changes may
lead to over-convergence of model outcomes as a result
of ‘group think’, so requiring models to retain their
original structure (i.e. their published versions or ver-
sions at the start of the model comparison process)
should be considered. Furthermore, care should be taken
that, as a result of any changes made, models do not fall
outside the previously set inclusion criteria for model
selection and that changes to the models do not result
in retrospective widening of the inclusion criteria. If
changes are allowed, any changes made during the exer-
cise need to be explicitly documented.
Exploring variability
Between- and within-model variability and uncertainty
should be explored
Exploring between- and within-model variability and un-
certainty is a fundamental part of the model comparison.
Scenario and sensitivity analyses should be part of the it-
erative process; the results of these analyses may lead to
changes in the models and to refining of the research
question (Fig. 2). It may be important to explore differ-
ent implementation strategies or to evaluate the impact
of the intervention in a variety of settings (e.g. with
different transmission characteristics) to inform decision-
makers.
Good practice
Multiple scenarios should be explored to understand the
drivers of the model results
To show the variability between models, a range of
different decision scenarios and outcomes should be
explored. As is performed for individual models, a
base-case scenario can be explored, followed by
several different scenarios. These scenarios should
include those most relevant to decision-makers but
might also reflect different hypotheses, for example,
based on epidemiological theory and previous model-
ling studies, on which model attributes might explain
differences in model predictions or outcomes. Scenar-
ios outside of the immediate relevance to the policy
decision might allow for a revealing comparison of
the impact of important parameters that vary among
models. By separately modifying the different aspects
of the model (e.g. biological, behavioural and demo-
graphic model parameters), it is possible to assess the
sensitivity of model output to alternative model struc-
tures. This allows modellers to explore and explain
the cause of different results [32, 33].
If the model comparison includes many models, it is pos-
sible to explore between-model variation and heterogeneity
Boon et al. BMC Medicine          (2019) 17:163 Page 8 of 13
in projected impact using a statistical approach such as a
(univariate) meta-regression analysis [32, 33].
Sensitivity analysis and what-if analyses (examining
extreme scenarios) should be carried out
Presenting the variability between models is one of
the core objectives of the model comparison exercise.
However, not only between-model heterogeneity
should be explored; within-model uncertainty should
also be assessed through sensitivity analysis. One pos-
sibility is examining extreme scenarios such as a best-
case and a worst-case scenario, where all parameters
are set at extreme but plausible values that are
favourable or unfavourable. Ideally, probabilistic sensi-
tivity analysis should also be performed. Probabilistic
sensitivity analysis reflects the combined effects of un-
certainty in the value of all the parameters and pro-
vides confidence intervals around point estimates (e.g.
the base-case results) for each of the models.
Performing sensitivity analysis for multiple models al-
lows for the testing of the boundaries of consensus.
Presenting and pooling results
Results should be presented in an appropriate way to
support decision-making
The results of multi-model comparisons for decision-
making should be understandable for the policy-maker.
At a minimum, the model results should be described in
a qualitative manner, i.e. whether they support or reject
a given policy of interest. This is easier when the models
are in consensus about the answer to the policy ques-
tion. If the models do not agree, the modellers should
try to explore and explain the underlying causes for
these differences. Furthermore, modellers should present
the strengths and limitations of the research findings
and address the quality of the models included in the
comparison. Depending on the research question and
the degree of heterogeneity in the model results, the
results of multiple models may be pooled to provide one
Fig. 2 The multi-model harmonisation and comparison process
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summary estimate plus the variability around that
estimate.
Good practice
The results for the individual models should be presented
along with within-model uncertainty ranges
Presenting the results of the individual models allows
those interpreting and using the findings of the model
comparison to assess the variability between the models.
Tables, graphs and other visuals can synthesise the large
amount of data generated in a model comparison and
such visualisations are often preferable to summarising
such data in a single pooled estimate.
In addition to the variation between models, the re-
sults should show the uncertainty within the different
models. The results of (probabilistic) sensitivity analyses
can be shown as 95% prediction intervals around the
model predictions [31]. However, because the various
models may use differing approaches to sensitivity ana-
lysis, the reported uncertainty may represent something
different for each model. Therefore, uncertainty ranges
should never be pooled. Modellers should clearly report
the sources of uncertainty for the individual models and
the degree to which models have explored uncertainty.
Summary measures that combine outcomes of models
should only be used if all outcomes support the same
policy. It should be clearly communicated whether
summary ranges include within-model uncertainty or
between-model uncertainty (i.e. the range of point
estimates across the model)
Multi-model comparisons often create a large array of
outcome data, particularly when many models are
included and different scenarios are explored. In such
instances, it might be helpful to synthesise model pre-
dictions by pooling. In other situations, a specific aim
of the model comparison might be to provide some
averaged prediction from different models [13, 34, 35].
However, the pooling of results is challenging because
models treat uncertainty differently; therefore, this can
only be done when models are sufficiently harmonised. If
there is a considerable disagreement between the models,
modellers should calculate and communicate the uncer-
tainties whilst still providing an accessible message to
end-users.
A relatively simple way to summarise results is by
majority vote, provided that all the models carry equal
weight in terms of reliability. For example, it is possible to
show the proportion of posterior estimates across models
that supports the decision (e.g. the cost-effectiveness of an
intervention). This then includes the uncertainty within
each model.
Another summary method is the median, shown to-
gether with the variability of the model outcomes, for
example, by showing the minimum and maximum esti-
mates and/or posterior values of the models. Such
pooled results illustrate the central tendency and vari-
ability or robustness of model predictions. In principle,
summary statics across models should not be presented
or interpreted as sampling distributions for statistical
inference such as is done in meta-analyses. Second mo-
ments, such as variance or distribution centiles, should
probably be avoided. If models are pooled without apply-
ing any weights, then implicitly equal weights for all
models are assumed. If such an approach is used, model-
lers should explicitly acknowledge the equal weighting.
A (weighted) mean of model outputs might be a useful
method to reduce prediction error for statistical models.
For these models, which are data driven, it is possible to
obtain model weights from some measure of a model’s
ability to simulate observed data (i.e. a model quality
metric or index) [13, 36]. However, these methods are
still being developed and naïve approaches to weighing,
e.g. averaging with equal scores or assigning subjective
weights, is discouraged until the underlying science has
been developed and proven.
Some model parameter and structure choices are not
driven by empirical data but rather by subjective beliefs
and values. Examples include the existence (or other-
wise) of a biological phenomenon based on theoretical
rather than empirical reasoning, and many methodo-
logical parameters in health economic models (such as
the economic perspective). In this case, the included
weights cannot be based on a likelihood measure
because there are no data to inform beliefs about the dif-
ference between model output and expected population
benefits and/or costs. Defining a set of criteria for a
model to be ‘credible’ or agreeing on a quality metric is
often difficult and there is currently no robust approach
for assigning weights to individual model projections.
Thus, for many model comparisons, weighting models
and/or pooling results is not an appropriate strategy.
Instead, it may be better to consider using scenario sen-
sitivity analysis, i.e. presenting results from all models
using alternative scenarios.
Interpretation
Results should be interpreted to inform the policy
question
The results must be interpreted with a focus of maximis-
ing the utility of the interpretation to inform the policy
question. This should be done simply and clearly. Key
results and their meaning to address the policy question
should be summarised, followed by a discussion of the
key strengths and limitations of the analysis, and, finally,
reporting of the next steps. Involving decision-makers
during the inception and interpretation phase ensures
that the decision-making context is considered and that
Boon et al. BMC Medicine          (2019) 17:163 Page 10 of 13
the results of the model comparison can be used by pol-
icy-makers.
Good practice
Key results and their interpretation to policy questions
should be discussed
The modellers should provide an unbiased assessment of
the modelling evidence and a cautious summary of what
they might mean to the decision-maker. If the evidence
warrants, a particular strategy should be recommended.
To avoid ambiguity, it is encouraged also to report on
what results do not mean. Evidence providers should
not feel pressured by decision-makers to deliver over-
confident or simplistic summaries that hide uncertainty.
Mathematical models only address one aspect of a policy
question, and the results of a multi-model comparison
should be considered together with other evidence such
as the feasibility, acceptability and ethical dimensions of
a strategy. Thus, the results from a multi-model com-
parison should be considered as inputs into a decision-
making process (such as a health technology assessment)
that considers a wider range of relevant criteria.
Key strengths and limitations of the model comparison
process and results should be addressed
Key strengths and limitations of the analysis should be
summarised, with equal emphasis given to both. It may
be useful if this could be performed by someone inde-
pendent of the modelling groups but with input and
agreement from all groups. The following items could be
addressed: generalisability of results (and/or the conse-
quence of using hypothetical settings), limitations of
scenarios explored, assumptions and simplifications
made, time and resource constraints that might have
limited the analysis, and the selection of included
models. Reasons for heterogeneous or divergent results
should be explored. Uncertainty should be discussed,
even if models give similar results.
It is important to note that agreement between models
is not evidence for increased confidence in the results
because the selection of models is unlikely to compre-
hensively explore the entire space of model structure
and parameter possibilities. Some features are likely to
be shared by many models as a result of the modellers
making similar assumptions and simplifications. Agree-
ment between models might also, in part, reflect a level
of shared process representation or calibration on
particular datasets and does not necessarily imply a
higher likelihood of the common answer being ‘correct’.
Researchers should avoid speculation and report on
the face validity of results, for example, by evaluating the
evidence in line with other considerations.
Key recommendations for next steps should be reported
Key recommendations for next steps should be reported
and questions that remain unanswered should be
highlighted. The researchers should explain what further
work is needed to increase certainty, for example, add-
itional data collection and further model analysis. The
variation in model results in a multi-model comparison
can serve to highlight existing uncertainties and key
directions for further data collection such as data short-
comings or lack of information about the natural history
of disease [2]. These gaps should be identified and pre-
sented to decision-makers in the hope that they will
invest in new research and data collection to advance
future decision-making.
Conclusion
These guidelines should help researchers plan, conduct
and report model comparisons of infectious diseases and
related interventions in a systematic and structured
manner for the purpose of supporting health policy deci-
sions. Adherence to these guidelines will contribute to
greater consistency and objectivity in the approach and
methods used in multi-model comparisons, and as such
improve the quality of modelled evidence for policy. Fur-
thermore, we hope that the guidelines will also help pol-
icy-makers and others interested in multi-model
comparisons to more easily understand and appraise the
methodology used as well as the strengths and limita-
tions of multi-model comparisons.
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